Patent Issued for Bicyclic peptide ligands specific for TSLP (USPTO 11866518).

A patent has been issued for bicyclic peptide ligands specific for TSLP (thymic stromal lymphopoietin), a cytokine involved in the pathogenesis of asthma. The invention provides a peptide ligand that binds to TSLP and a pharmaceutical composition containing the ligand. The ligand can be used to prevent, suppress, or treat diseases or disorders mediated by TSLP. Asthma is a common long-term inflammatory disease of the airways, and there is a need for therapeutic agents to alleviate its symptoms. The patent was filed by BicycleTx Limited and published in January 2024. [Extracted from the article]